Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ILDAJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PTM-001-ADC
|
|||||
| Synonyms |
PTM 001 ADC; PTM-001 ADC
Click to Show/Hide
|
|||||
| Organization |
Ptm Therapeutics, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Colon cancer [ICD11:2B90]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
1.6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Emtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.